DeepMed Research

Utidelone

Generic Name: Utidelone

Drug Type: Small Molecule

Background: Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering. It is under investigation in clinical trials for various cancers.

Indication: 联合卡培他滨，用于既往接受过至少一种化疗方案的复发或转移性乳腺癌患者。

Clinical Trials

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer
Neoadjuvant Therapy

Interventions: Drug: Utidelone
Drug: Carboplatin
Drug: Epirubicin
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2023-08-09

Last Posted Date: 2023-08-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 181

Registration Number: NCT05983094

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma

Phase 2

Recruiting

Conditions: Metastatic Urothelial Carcinoma

Interventions: Drug: utidelone injection

First Posted Date: 2023-06-09

Last Posted Date: 2023-06-09

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 34

Registration Number: NCT05895864

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

Phase 2

Recruiting

Conditions: Esophageal Cancer

Interventions: Drug: Utidelone and anlotinib

First Posted Date: 2023-05-19

Last Posted Date: 2023-05-19

Lead Sponsor: Peking University

Target Recruit Count: 47

Registration Number: NCT05866510

Locations: 🇨🇳
Suining Central Hospital, Suining, Sichuan, China
🇨🇳
Beijing Cancer Hospital, Beijing, China, Beijing, China
🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, China

Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Neoplasms

Interventions: Drug: Utidelone injection in combination with gemcitabine

First Posted Date: 2023-04-03

Last Posted Date: 2023-04-03

Lead Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 92

Registration Number: NCT05795920

Locations: 🇨🇳
Shanghai First People's Hospital, Shanghai, Shanghai, China

Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: Utidelone Capsule (Part 1)
Drug: Capecitabine
Drug: Utidelone Capsule (Part 3)

First Posted Date: 2023-01-26

Last Posted Date: 2024-04-19

Lead Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.

Target Recruit Count: 84

Registration Number: NCT05700084

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: Utidelone Capsule

First Posted Date: 2023-01-11

Last Posted Date: 2023-11-09

Lead Sponsor: Biostar Pharma, Inc.

Target Recruit Count: 28

Registration Number: NCT05681000

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Docetaxel Injection in combination with AC
Drug: Utidelone Injection in combination with AC

First Posted Date: 2023-01-06

Last Posted Date: 2023-11-08

Lead Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.

Target Recruit Count: 552

Registration Number: NCT05673629

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: Utidelone Injection
Drug: Docetaxel Injection

First Posted Date: 2023-01-06

Last Posted Date: 2023-11-08

Lead Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.

Target Recruit Count: 612

Registration Number: NCT05673590

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Phase 3

Recruiting

Conditions: Locally Advanced or Metastatic Breast Cancer
Breast Neoplasms

Interventions: Drug: utidelone
Drug: docetaxel

First Posted Date: 2022-06-24

Last Posted Date: 2023-07-13

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 349

Registration Number: NCT05430399

Locations: 🇨🇳
Shusen Wang, Guangzhou, Gangdong, China
🇨🇳
Hunan Cancer Hospital, Hunan, Hunan, China

Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Neoplasms
Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: utidelone

First Posted Date: 2022-06-03

Last Posted Date: 2022-06-03

Lead Sponsor: Fudan University

Target Recruit Count: 61

Registration Number: NCT05403333

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy